Roche taps Dyno Therapeutics' AI-driven capsids for neurological gene therapy
Genetic Engineering & Biotechnology News (GEN) - 15-Jan-2025A partnership advancing synthetic AAV vectors to tackle gene therapy challenges
Join the club for FREE to access the whole archive and other member benefits.
Biotechnology company that uses artificial intelligence for gene therapy
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.
Our team includes world-class molecular and synthetic biologists, protein engineers and gene therapy scientists working alongside software engineers, data scientists, and AI and machine learning experts.
As we create AI-powered gene therapies that enhance the life-changing potential of gene therapies for millions of patients, we believe the future is within reach.
Visit website: https://www.dynotx.com/
Details last updated 28-Apr-2023
A partnership advancing synthetic AAV vectors to tackle gene therapy challenges
They aim to use AI-driven capsid design for delivery for complex treatments
Is involved in many longevity companies ranging from improving gene therapy delivery to supplements
The biotech’s AI platform aims to unlock new treatments for severe diseases